Cite
HARVARD Citation
Ryoo, B. et al. (2021). Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240. Cancer. 127 (6), pp. 865-874. [Online].